RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNXT RenovoRx Inc

Trading 04-16 11:18:25 EDT

0.9926

-0.0274

-2.69%

High1.04	Low0.9900	Vol35.54K
Open1.04	D1 Closing1.02	Amplitude4.90%
Mkt Cap44.72M	Tradable Cap42.81M	Total Shares45.05M
T/O35.72K	T/O Rate0.08%	Tradable Shares43.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RNXT","market":"US","secType":"STK","nameCN":"RenovoRx Inc","latestPrice":0.9926,"timestamp":1776352546256,"preClose":1.02,"halted":0,"volume":35542,"delay":0,"changeRate":-0.026862745098039195,"floatShares":43131400,"shares":45052700,"eps":-0.316077,"marketStatus":"Trading","change":-0.0274,"latestTime":"04-16 11:18:25 EDT","open":1.04,"high":1.04,"low":0.99,"amount":35722.883900600005,"amplitude":0.04902,"askPrice":0.9999,"askSize":500,"bidPrice":0.9925,"bidSize":157,"shortable":3,"etf":0,"ttmEps":-0.316077,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776369600000},"marketStatusCode":2,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":1.02,"preHourTrading":{"tag":"盘前","latestPrice":1,"preClose":1.02,"latestTime":"09:28 EDT","volume":813,"amount":814.8232338,"timestamp":1776346121467,"change":-0.02,"changeRate":-0.019608,"amplitude":0.023922},"postHourTrading":{"tag":"盘后","latestPrice":1.0108,"preClose":1.02,"latestTime":"19:34 EDT","volume":2262,"amount":2283.485,"timestamp":1776296081224,"change":-0.0092,"changeRate":-0.00902,"amplitude":0.019608},"volumeRatio":0.410701},"requestUrl":"/m/hq/s/RNXT/tweets","defaultTab":"tweets","newsList":[{"id":"2627461914","title":"RenovoRx says TAMP study shows reduced tumor activity in pancreatic cancer patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2627461914","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627461914?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:32","pubTimestamp":1776169979,"startTime":"0","endTime":"0","summary":"RenovoRx reported clinical data on its TAMP targeted chemotherapy delivery platform that were presented April 13, 2026 at Society of Interventional Radiology Annual Scientific Meeting.Study from Moffitt Cancer Center indicated local delivery of gemcitabine near tumor site could support treatment response in locally advanced pancreatic cancer while limiting systemic toxicity.Post-treatment PET/CT imaging showed reduced tumor metabolic activity, suggesting response even when tumor size changed little.Results were positioned as supportive evidence for RenovoRx’s ongoing Phase III TIGeR-PaC trial of intra-arterial gemcitabine delivered via RenovoCath for locally advanced pancreatic cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL8rN9ky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","NDAQ","SG9999014013.SGD","BK4585","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014021.USD","BK4112","RNXT","LU0314104364.USD","SG9999014039.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4588","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626252529","title":"RenovoRx Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2626252529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626252529?lang=en_us&edition=fundamental","pubTime":"2026-04-09 00:50","pubTimestamp":1775667000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNXT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 12:50 ET (16:50 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625694424","title":"RenovoRx secures Japanese patent allowance for targeted drug-delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2625694424","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625694424?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:16","pubTimestamp":1775654189,"startTime":"0","endTime":"0","summary":"RenovoRx (RNXT) announced that the Japan Patent Office has issued a Notice of Allowance for the company’s first Japanese patent application titled ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-secures-japanese-patent-allowance-for-targeted-drug-delivery-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-secures-japanese-patent-allowance-for-targeted-drug-delivery-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNXT","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625949490","title":"RenovoRx wins Japan patent allowance for RenovoCath drug-delivery device","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949490","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949490?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:31","pubTimestamp":1775651473,"startTime":"0","endTime":"0","summary":"RenovoRx reported Japan Patent Office issued a Notice of Allowance for its first Japanese patent application covering RenovoCath drug-delivery via vasa vasorum.Application JP 2024-559262 is titled “Method and Apparatus for Delivering an Agent Through the Vasa Vasorum.”Allowed claims cover a dual-occlusion catheter system with integrated imaging and pressure sensing for localized, controlled infusion of drugs or biologics.RenovoRx said patent position supports commercialization strategy in Japan alongside ongoing US commercialization of RenovoCath.Company reported 19 issued or allowed patents globally, with 14 pending.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9ghR5t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","IE00B64PRP62.GBP","BK4112","BK4585","IE00BN0W2V16.EUR","RNXT","SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624546592","title":"RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624546592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624546592?lang=en_us&edition=fundamental","pubTime":"2026-04-02 02:20","pubTimestamp":1775067600,"startTime":"0","endTime":"0","summary":"RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and MoreMOUNTAIN VIEW, Calif., April  01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-scie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/01/3266942/0/en/RenovoRx-Named-to-Fast-Company-s-Annual-List-of-the-World-s-Most-Innovative-Companies-of-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4139","BK4539","RNXT","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624600532","title":"Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624600532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624600532?lang=en_us&edition=fundamental","pubTime":"2026-04-01 03:30","pubTimestamp":1774985408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbSci (ABSI) and RenovoRx (RNXT) with bullish sentim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-absci-absi-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-absci-absi-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","HCSG","BK4139","XBI","BK4137","BK4121","BK4585","BK4588","LU0128526141.USD","BK4539","RNXT","ABSI","LU0029874061.USD","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623972329","title":"RenovoRx Q4 EPS $(0.08), Inline, Sales $238.000K Miss $419.750K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623972329","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623972329?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:22","pubTimestamp":1774902159,"startTime":"0","endTime":"0","summary":"RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.12) per share from the same period last year.  The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51553172/renovorx-q4-eps-0-08-inline-sales-238-000k-miss-419-750k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"RenovoRx Q4 EPS $(0.08), Inline, Sales $238.000K Miss $419.750K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329353","title":"RenovoRx net loss widens to $11 million in FY25; revenue climbs to $1.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329353","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329353?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:12","pubTimestamp":1774901530,"startTime":"0","endTime":"0","summary":"RenovoRx posted a net loss of $11.2 million for full-year 2025.Revenue rose to $1.1 million in its first full year of RenovoCath commercialization.Operating loss widened to $12.5 million on higher selling, general and administrative expenses tied to commercial infrastructure buildout.RenovoCath adoption expanded to 12 active U.S. cancer centers as of Feb. 27, 2026, with 21 additional centers in evaluation or preparing for activation.TIGeR-PaC Phase III trial remained on track for enrollment completion by mid-2026, with final data anticipated in 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL3SZLFy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","BK4539","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","BK4588","IE00BKPKM429.USD","BK4139","SG9999014021.USD","NDAQ","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014039.USD","LU2210150020.SGD","BK4585","SG9999014013.SGD","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623326740","title":"BRIEF-RenovoRx FY Net Income USD -11.168 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623326740","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623326740?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:05","pubTimestamp":1774901146,"startTime":"0","endTime":"0","summary":"BRIEF-RenovoRx FY Net Income USD -11.168 Million\n\n\nMar 30 (Reuters) - RenovoRx FY operating expenses USD 13.306 million.\n\nFY basic EPS USD -0.32","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nPLX62E9F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623760326","title":"RenovoRx FY Basic EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2623760326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623760326?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:05","pubTimestamp":1774901102,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nPLX62E9F6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623293493","title":"RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623293493","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623293493?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:05","pubTimestamp":1774901100,"startTime":"0","endTime":"0","summary":"RenovoCath Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3265014/0/en/RenovoRx-Reports-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","MAB","BK4539","IAG","LU0345780521.USD","BK4139","LU0345780281.USD","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315199","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315199?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:00","pubTimestamp":1774864800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.26)  4:05 PM. ·Dave & Buster                                   4Q       .39   4:05 PM. ·NIKE Class B                                     3Q       .29   4:15 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INV","NMRA","APOG","IMNN","NNOX","RNXT","BEEM","PROP","AIRO","NKE","NEOG","MAZE","NKLR","CAG","CRDL","JILL","BTBT","LW","PVH","BHST","DMAC","BNZI","FC","MKC","AEHR","NCNO","PRPL","SGML","AURA","BIRD","INMB","SGMO","BITF","PENG","LNN","MSM","CALM","AIRJ","PRGS","PLAY","BCAX","PVLA","BYND","RH","FDS","KEEL","PHR","MKC.V","NGEN","AYI","ANGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622803433","title":"RenovoRx Inc  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622803433","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622803433?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:05","pubTimestamp":1774645506,"startTime":"0","endTime":"0","summary":"RenovoRx Inc  expected to post a loss of8cents a share - Earnings Preview RenovoRx Inc RNXT.OQ RNXT.O is expected to  show a rise in quarterly revenue when it reports  results on March 30 for the peri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F23M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823371","title":"RenovoRx Inc - Appoints Ramtin Agah as Executive Chairman Effective February 27, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823371?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:03","pubTimestamp":1774609383,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F02G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622982333","title":"RenovoRx appoints Ramtin Agah executive chairman; base salary rises to $450,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622982333","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622982333?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:01","pubTimestamp":1774609306,"startTime":"0","endTime":"0","summary":"RenovoRx appointed Ramtin Agah to the newly created role of Executive Chairman, effective Feb. 27, 2026.Agah also serves as the company’s Chief Medical Officer and Chairman of the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL7fDm62:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUTL","BNZI","DMAC","BTBT","AEHR","AYI","BCAX","MKC.V","IMNN","NEOG","NGEN","KOPN","RNXT","DEFT","NKLR","LW","MKC","FDS","BYND","NKE","KYTX","CRDL","NMRA","LNN","APOG","JILL","PLAY","AIRO","MSM","AURA","ANGO","NCNO","INMB","HUMA","BEEM","MSLE","PENG","CAG","KEEL","CALM","LGN","BIRD","BHST","FC","PRGS","INV","BITF","ATOS","AIRJ","PHR","CCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622024521","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024521?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:00","pubTimestamp":1774432800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","AUTL","BAK","ABOS","CCL","EDAP","AIRJ","IMDX","JILL","CNTB","GOVX","AGX","KOD","AIRO","BNZI","IKT","CDLR","NKE","IMNN","BITF","EQ","BTGO","HUMA","FUL","CNTA","FDS","CGTX","CHWY","CELC","HYPD","FEMY","JBS","CTAS","MKC","BIRD","CGNT","JEF","CNTX","DEFT","DOO","EPAC","KALV","BYND","RNXT","DMAC","AURA","CMC","DERM","BHST"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622010862","title":"RenovoRx director Laurence Marton acquires USD 10,000 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622010862","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622010862?lang=en_us&edition=fundamental","pubTime":"2026-03-25 09:17","pubTimestamp":1774401451,"startTime":"0","endTime":"0","summary":"RenovoRx director Laurence Marton reported acquiring 9,720 shares of common stock.The filing shows 9,720 shares held indirectly through the Laurence Marton Rollover IRA.Marton also reported acquiring 4,860 warrants with an exercise price of USD 1.93.The warrants position was reported as 4,860 held indirectly through the Laurence Marton Rollover IRA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL9RLyPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622861010","title":"RenovoRx CEO Shaun Bagai reports USD 25,000 acquisition of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622861010","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622861010?lang=en_us&edition=fundamental","pubTime":"2026-03-25 09:17","pubTimestamp":1774401436,"startTime":"0","endTime":"0","summary":"RenovoRx Chief Executive Officer and director Shaun Bagai reported the purchase of 24,300 shares of common stock.Following the reported transaction, The Bagai Family Trust beneficially owned 313,357 shares indirectly.A warrant position for 12,150 shares was reported with an exercise price of USD 1.93.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLCQscr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx CEO Shaun Bagai reports USD 25,000 acquisition of common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622017152","title":"RenovoRx CFO Mark Voll files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622017152","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622017152?lang=en_us&edition=fundamental","pubTime":"2026-03-25 09:00","pubTimestamp":1774400450,"startTime":"0","endTime":"0","summary":"Mark Voll, RenovoRx’s Chief Financial Officer, reported owning 25,000 shares of common stock in an initial Form 3 filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL30gKNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovorx.com;renovorx.com","stockEarnings":[{"period":"1week","weight":0.0863},{"period":"1month","weight":0.0482},{"period":"3month","weight":-0.0097},{"period":"6month","weight":-0.0893},{"period":"1year","weight":0.1333},{"period":"ytd","weight":0.2141}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.049533},{"month":2,"riseRate":0.6,"avgChangeRate":0.102207},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093103},{"month":4,"riseRate":0.2,"avgChangeRate":-0.129863},{"month":5,"riseRate":0.5,"avgChangeRate":0.046228},{"month":6,"riseRate":0.5,"avgChangeRate":0.03467},{"month":7,"riseRate":0.25,"avgChangeRate":-0.034228},{"month":8,"riseRate":0.25,"avgChangeRate":-0.119414},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050074},{"month":10,"riseRate":0,"avgChangeRate":-0.120676},{"month":11,"riseRate":0.6,"avgChangeRate":0.028303},{"month":12,"riseRate":0.6,"avgChangeRate":0.479671}],"exchange":"NASDAQ","name":"RenovoRx Inc","nameEN":"RenovoRx Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RenovoRx Inc,RNXT,RenovoRx Inc股票,RenovoRx Inc股票老虎,RenovoRx Inc股票老虎国际,RenovoRx Inc行情,RenovoRx Inc股票行情,RenovoRx Inc股价,RenovoRx Inc股市,RenovoRx Inc股票价格,RenovoRx Inc股票交易,RenovoRx Inc股票购买,RenovoRx Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction